Supplemental Figures Figure S1: Non-truncating variants visualised in tolerance landscape of POU3F3
Tolerance landscape of the POU3F3 protein based on transcript NM_006236.2 (ENST00000361360.2) visualized via the MetaDome web server 1 . The tolerance landscape is computed based on single nucleotide variants present in the gnomAD database. It is calculated as a missense over synonymous ratio in a sliding window of 21 residues over the entire POU3F3 protein. The green and blue peaks correspond to regions more tolerant to missense variation, and the red valleys indicate intolerant regions. The locations of the non-truncating variants in our cohort are displayed within the tolerance landscape of POU3F3. All these variants are located in regions that are highly intolerant to missense variation. A detailed visualization of the three-dimensional modeling analysis for the two missense variants affecting amino acids that directly bind to the major groove of DNA . Wild-type residues are shown in blue, while substitutions (caused by variants) are shown in magenta. DNA is depicted in yellow.
A) Arg362 (blue) is able to form hydrogen bonds with guanine in the DNA binding site. This binding is disturbed by substitution into leucine (magenta). B) Asn456 (blue) is able to form hydrogen bonds with adenine in the DNA binding site. This binding is disturbed by substitution into serine (magenta).
Figure S3: Immunoblot analysis
Western blot analysis of whole-cell lysates expressing eleven different YFP-tagged constructs, probed with an anti-EGFP antibody: wild-type POU3F3, nine different POU3F3 variants and wild-type POU3F2. The immunoblot was stripped and then re-probed with beta-actin as a loading control. All different expressed YFP-fusion proteins are visible at the expected molecular weights. 
Figure S4: Aberrant subcellular localization patterns in a subset of cells for four variants

Figure S5: POU3F3 binding site in intronic region of FOXP2
This figure shows the ~300bp region of intron 8 of FOXP2 (chr7:114,289,482-114,289,778 (hg19/GRCh37)), that was cloned into a luciferase reporter vector to investigate transcriptional activation. The previously described POU3F2 consensus binding site 2 is shown in red.
Supplemental Material and Methods
Research subjects
Informed consent was obtained from all participating families. For all pictures of probands in this study, specific consent to publish clinical photographs was obtained. All procedures in this study matched the local ethical guidelines of the participating centres, and are in accordance with the Declaration of Helsinki. Probands with possible pathogenic POU3F3 variants were found using the GeneMatcher website 3 , the Decipher Database 4 and matchbox 5 , and table S1 contains details on which specific matchmaking platform was used to identify each individual.
Exome sequencing, variant filtering and annotation
Exome sequencing and variant filtering were performed as previously described [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . In individuals 1-17, whole exome sequencing and variant filtering was performed using a trio approach, in which sequencing was performed in the proband and both parents. In individual 18 and 19, whole exome sequencing was performed with a duo approach, in which the proband (individual 18) and the mother (individual 19) were sequenced. In all individuals, the POU3F3 variant was considered to be the most likely variant contributing to the phenotype, and there were no additional pathogenic or likely pathogenic variants reported. Additional variants (SNVs and CNVs) considered to be possibly pathogenic and/or to possibly contribute to the phenotype, are listed in Table S1 . All variants in this study are annotated with respect to the NM_006236.2 transcript.
Cell culture and transfection
Human embryonic kidney cells 293 (HEK293) cells were grown in Dulbecco's Modified Eagle's Medium (Gibco) that was supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin mix (both Gibco). The cells were cultured at 37°C in an incubator with 5% CO2. Transient transfection was performed with GeneJuice Transfection Reagent (Merck MilliPore) according to the manufacturer's instructions.
Cloning of DNA constructs and site-directed mutagenesis
A synthetic clone of wildtype POU3F3 cDNA with flanking restriction sites EcoR1 and Xba1 in a pUC57-vector was synthesized by GenScript. The POU3F3 insert was subcloned using the EcoR1/Xba1 restriction sites into a modified pLuc and pYFP vector as previously described 18 .
Variants in POU3F3 constructs were created using site-directed mutagenesis (SDM) with the QuikChange II Site-Directed Mutagenesis Kit (Agilent) according to the manufacterer's instructions.
The insert) was used as a control construct for the luciferase assays.
POU3F2 cDNA was cloned into TOPO vector using the following primers: 5'-GAGGATCCTGGCGACCGCAGCGTCTAACCAC-3' (Forward primer) and 5'-GATCTAGATTACTGGACGGGCGTCTGCACCCCG-3' (Reverse primer). The POU3F2 insert was then subcloned into modified pLuc and pYFP vectors (as previously described; 18 ) using BamHI and XbaI restriction sites.
To create the firefly reporter construct for luciferase assays, the previously described POU3F2 binding site in FOXP2 ( Figure S5 ) was cloned into TOPO from gDNA using the following primers: 5'-CTCGAGTAGGCACTGACTGAGAAAATC-3' (Forward primer) and 5'-AGATCTATATGTAAAAGAATAGTGCCT-3' (Reverse primer). The binding site was then subcloned into a p.GL4.23 vector (Promega) using the restriction sites BglII and XhoI.
Control constructs used in the BRET assays (pYFP-vector with NLS-insert, and pRLuc-vector with NLSinsert) were made as previously described 18 . All constructs were validated by Sanger sequencing.
Subcellular localization
HEK293 cells were seeded on poly-D-lysine (Sigma) coated coverslips, and transfected after 24 hours.
At 36 hours post-transfection, the cells were fixed by incubation in 4% Paraformaldehyde (Electron Microscopy Sciences) for ten minutes at room temperature. Coverslips were mounted onto slides using Vectashield mounting medium for fluorescence with DAPI (Vector). The proteins of interest were expressed as fusion proteins to YFP. Fluorescence images were obtained with an Axiovert A-1 fluorescence microscope and ZEN imaging software (Zeiss).
BRET assay HEK293 cells were transfected 24 hours after plating in 96 well plates, with pairs of Renilla luciferase and YFP fusion proteins, as previously described 18 The BRET assay set-up that was used for this study is discussed in more detail in Deriziotis et al. 18 .
Luciferase assay HEK293 cells were transfected 24 hours after seeding in 96 well plates with the firefly luciferase reporter construct (2µl of 36nM), a pGL4.74 (hRluc/TK) Renilla Reniformis luciferase construct (2µl of 36nM; Promega) and a YFP-expression construct or empty YFP-expression vector (6µl of 36nM).
Firefly luciferase and Renilla luciferase activities were measured 36 hours post-transfection using the room temperature, and blocked in 5% milk in PBS-T for 30 minutes at room temperature, followed by incubation with 1:1000 mouse anti-beta-actin (Sigma) in 1% milk overnight at 4°C, and incubation with 1:3000 HRP-conjugated goat anti-mouse (Bio-Rad) in 1% milk at room temperature.
Three-dimensional modeling
The exact three-dimensional structure of human POU3F3 is not known. Therefore, we created a homology model based on the crystal structure of the mouse POU3F1 structure (PDB file 2XSD) 19 .
The human POU3F3 and mouse POU3F1 sequences show 94% identity over 147 residues in the Cterminal domain, containing both the POU-specific and the POU-homeo domain. We used the YASARA & WHAT IF Twinset modeling algorithm with standard parameters for modeling and subsequent analysis 20; 21 .
